Infrarenal by Choice

GORE® EXCLUDER® AAA Endoprosthesis

- Most studied EVAR device*
- EVAR market leader
- 300,000+ patients treated**
- Over 20 years of experience
- Low rates of:†
  - Migration
  - Type Ia endoleak
  - Reintervention
  - Limb occlusion
  - Renal complications

Proven performance. Proven outcomes.

The most-studied* EVAR device delivers durable outcomes for your patients.

3,273 Patients — Follow-up through 3 Years‡

0.6%	0.0%§	0.02%
Type Ia endoleak	Migration	Renal complications‖

GORE EXCLUDER® AAA ENDOPROSTHESIS

The GORE® C3® Delivery System is repositionable to obtain optimal seal

- A unique delivery system provides the ability to reconstrain the proximal end of the device and reposition for ideal placement
- More opportunities to maximize infrarenal seal



Data from GREAT:‡ 400 Patients, 13 EU sites, August 2010–December 2012

48.1% Physicians used repositioning

79%
Optimized position to renal arteries

20%
Contralateral gate cannulation

INDICATIONS FOR USE: Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components. The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac / femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation ≤ 60°; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. **Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components.** The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in patients with known sensitivities or allergies to the device materials and patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. ℞ Only

* Based on the company-sponsored trials and registries shown on clinicaltrials.gov, the GORE® EXCLUDER® AAA Device is the most studied of the currently available endografts.

** Based on the number of Trunk-Ipsilateral Legs distributed.

† Based on U.S. clinical studies and post-approval registries.

‡ Data from the Global Registry for Endobvascular Aortic Treatment (GREAT): GORE® EXCLUDER® AAA Device To calculate the overall event rates from procedure through end of period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site-reported serious adverse events.

§ One peri-procedural migration reported. Zero migrations reported during follow-up through 3 years.

‖ Includes serious adverse events MedDRA coded as renal failure and impairment

GORE
Creative Technologies Worldwide

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.

AW1847-EN1 DECEMBER 2017